Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

Virginia M. Klimek, Emily K. Dolezal, Larry Smith, Gerald Soff, Stephen D. Nimer

Research output: Contribution to journalArticle

6 Scopus citations


Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30. mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (. n=. 4) and ototoxicity (. n=. 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.

Original languageEnglish (US)
Pages (from-to)570-574
Number of pages5
JournalLeukemia Research
Issue number5
StatePublished - May 1 2012
Externally publishedYes



  • Acute myelogenous leukemia
  • Myelodysplastic syndromes
  • NF-κB
  • Sodium salicylate

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this